

Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies

Author(s):

Andreas Papadopoulos, MD¹; Konstantinos Palaiopoulos, MD²; Harry Björkbacka, PhD³; Annette Peters, PhD^{4, 5, 6, 7}; James A. de Lemos, MD⁸; Sudha Seshadri, MD^{9, 10, 11}; Martin Dichgans, MD^{12, 13, 14}; Marios K. Georgakis, MD, PhD¹²

Corresponding Author:

Marios K. Georgakis

marios.georgakis@med.uni-muenchen.de

Affiliation Information for All Authors: 1. Department of Radiology, 401 General Military Hospital of Athens, Greece; 2. National Public Health Organization, Athens, Greece; 3. Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden; 4. Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; 5. German Center for Diabetes Research (DZD), München-Neuherberg, Neuherberg, Germany; 6. German Research Center for Cardiovascular Disease (DZHK), Partner site Munich Heart Alliance, Germany; 7. Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany; 8. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; 9. National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, USA; 10. Department of Medicine, School of Medicine Boston University School of Medicine, Boston, MA, USA; 11. Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA; 12. Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University LMU, Munich, Germany; 13. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; 14. German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany

Contributions:

Andreas Papadopoulos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: statistical analysis

Konstantinos Palaiopoulos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Harry Björkbacka: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Additional contributions: study supervision

Annette Peters: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Additional contributions: study supervision

James A. de Lemos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Additional contributions: study supervision

Sudha Seshadri: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Additional contributions: study supervision

Martin Dichgans: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data; Additional contributions: study supervision

Marios K. Georgakis: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: statistical analysis, study supervision

Publication History: This manuscript was pre-published in medRxiv on March 29, 2021 under a CC-BY-NC-ND 4.0 International license. DOI: <https://doi.org/10.1101/2021.03.27.21254451>

Number of characters in title: 123

Abstract Word count: 345

Word count of main text: 4195

References: 50

Figures: 4

Tables: 1

Supplemental: 1. Reviewer responses_05.10.21.doc 2. Manuscript track changes_05.10.21.doc 3. 8 e-supplements (1 e-appendix, e-References, 1 e-table, 5 e-figures)

Statistical Analysis performed by: Statistical analysis was performed by A. Papadopoulos (MD; Department of Radiology, 401 General Military Hospital of Athens, Greece) and M. K. Georgakis (MD, PhD; German Centre for Neurodegenerative Diseases [DZNE], Munich, Germany)

Search Terms: [2] All Cerebrovascular disease/Stroke, [22] Clinical trials Systematic review/meta analysis, [59] Risk factors in epidemiology

Study Funding: H. Björkbacka is supported by the Swedish Research Council and the Swedish Heart-Lung Foundation. The analysis from the Framingham Heart Study has been funded from NHLBI: HHSN 268201500001I and NINDS grant R01 NS017950 (SS). M. Dichgans is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germanys Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy ID 390857198) and as part of CRC 1123 (B3) and DI 722/16-1. M. K. Georgakis has received funding from the Onassis Foundation, the German Academic Exchange Service, and the Vascular Dementia Research Foundation.

Disclosures: A. Papadopoulos reports no disclosures relevant to the manuscript; K. Palaiopoulos reports no disclosures relevant to the manuscript; H. Björkbacka reports no disclosures relevant to the manuscript; A. Peters reports no disclosures relevant to the manuscript; J. A. de Lemos reports no disclosures relevant to the manuscript; S. Seshadri reports no disclosures relevant to the manuscript; M. Dichgans reports no disclosures relevant to the manuscript; M. K. Georgakis reports no disclosures relevant to the manuscript

ABSTRACT

Background and Objectives: Human genetic studies support a key role of interleukin-6 (IL-6) in the pathogenesis of ischemic stroke. Still, there are only limited data from observational studies exploring circulating IL-6 levels as a risk factor for ischemic stroke. Here, we set out to perform a systematic review and meta-analysis of aggregate data on cohort studies to determine the magnitude and shape of the association between circulating IL-6 levels and risk of incident ischemic stroke in the general population.

Methods: Following the PRISMA guidelines, we systematically screened the PubMed search engine from inception to March 2021 for population-based prospective cohort studies exploring the association between circulating IL-6 levels and risk of incident ischemic stroke. We pooled association estimates for ischemic stroke risk with random-effects models and explored non-linear effects in dose-response meta-analyses. Risk of bias was assessed with the Newcastle-Ottawa scale (NOS). We used funnel plots and trim-to-fill analyses to assess publication bias.

Results: We identified 11 studies (n=27,411 individuals; 2,669 stroke events) meeting our eligibility criteria. Mean age of all included participants was 60.5 years and 54.8% were females. Overall, quality of the included studies was high (median 8 out of 9 NOS points, interquartile range 7 to 9). In meta-analyses, 1-standard deviation increment in circulating log-transformed IL-6 levels was associated with a 19% increase in risk of incident ischemic stroke over a mean follow-up of 12.4 years (RR 1.19; 95% CI 1.10 to 1.28). A dose-response meta-analysis showed a linear association between circulating IL-6 levels and ischemic stroke risk. There was only moderate heterogeneity and the

results were consistent in sensitivity analyses restricted to studies of low risk of bias and studies fully adjusting for demographic and vascular risk factors. The results also remained stable following adjustment for publication bias.

Discussion: Higher circulating IL-6 levels in community-dwelling individuals are associated with higher long-term risk of incident ischemic stroke in a linear pattern and independently of conventional vascular risk factors. Along with findings from genetic studies and clinical trials, these results provide additional support for a key role of IL-6 signaling in ischemic stroke.

INTRODUCTION

Stroke is a leading cause of adult disability and mortality worldwide.^{1, 2} Identifying risk factors for stroke is important for developing effective primary and secondary preventive strategies. Inflammation has recently attracted attention as a potential target for lowering ischemic stroke risk.^{3, 4} Data from large-scale trials⁵⁻⁷ have provided proof-of-concept evidence that anti-inflammatory approaches can lower cardiovascular risk. Still, these trials tested combined cardiovascular endpoints and evidence regarding the utility of anti-inflammatory approaches specifically for stroke prevention is scarce.⁸

Developing effective anti-inflammatory approaches for stroke prevention would require identifying key inflammatory mediators involved in stroke pathogenesis.^{9, 10} While there is extensive literature regarding the association of C-reactive protein (CRP) levels, a general marker of inflammation, with stroke,¹¹ there is only limited data regarding other inflammatory cytokines. Data from human genetic studies have suggested a potentially causal role of the pro-inflammatory cytokine interleukin-6 (IL-6) in vascular disease,¹²⁻¹⁴ thus making it a promising drug target.

Moving towards anti-inflammatory treatments specifically targeting IL-6 signaling¹⁵ would benefit from clarifying the magnitude and shape of the association between circulating IL-6 levels and ischemic stroke. While prospective cohort studies have established robust associations between circulating IL-6 levels with risk of coronary artery disease,¹⁶ there is only limited evidence regarding associations with ischemic stroke,¹⁷⁻¹⁹ which also entails mechanisms other than atherosclerosis. Here, we set out to leverage aggregate data from published literature along with unpublished cohort studies in a systematic review and meta-analysis in order to explore the association of

circulating IL-6 levels and risk of incident ischemic stroke in population-based prospective cohort studies.

METHODS

This systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement guidelines.²⁰

Search strategy

Two independent reviewers (A.P. and K.P.) systematically screened the medical search engine PubMed from inception to March 4, 2021. We searched for cohort studies investigating the association between circulating IL-6 levels and risk of ischemic stroke using a combination of the predefined key words “interleukin-6”, “IL-6”, “stroke”, and “cerebrovascular disease”. Reference lists of eligible articles were hand-searched for possible eligible studies not identified through the primary database search (“snowball procedure”). No language or publication year restrictions were applied. Eligible studies were assessed for potential population overlap according to recruitment period, geographical site, study name, and sample size. In case of overlap, we included the study with the largest number of incident events. We also contacted the corresponding authors of studies, which did not present the desired analysis but presented the required variables, to request for additional data.

Eligibility criteria

Eligible studies should be of a prospective cohort design. Case-cohort and nested case-control analyses within prospective cohorts, as well as prospective *post hoc* analyses from randomized clinical trials, were also considered eligible. Case-control and cross-sectional studies, case series, case reports, systematic or narrative reviews, as well as animal and *in vitro* studies were excluded. Eligible studies should preferably be based on the general population. Studies on high-risk populations, such as populations with conventional vascular risk factors (e.g., diabetes mellitus or hypertension), but free of stroke at baseline, were also included. Studies including solely individuals with a history of stroke were excluded, as did studies in very specific high-risk populations, such as individuals with advanced chronic kidney disease on hemodialysis.

The exposure variable of interest was circulating IL-6 levels quantified in plasma or serum by immunoassay methods. Due to the lack of universally accepted IL-6 normal value range and differences across the variable laboratory kits used by individual studies, we analyzed IL-6 in standardized (1-standard deviation [SD] increment) and not absolute values.

We included studies that explored associations between circulating IL-6 levels and risk of incident ischemic stroke defined according to standardized clinical criteria. We excluded studies examining associations with: (i) a combined cardiovascular endpoint also including ischemic stroke, but not providing association estimates for ischemic stroke; (ii) clinically silent brain infarcts; (iii) stroke mortality; (iv) TIAs; (v) recurrent stroke; and (vi) hemorrhagic stroke. Studies examining combined endpoints of ischemic

and hemorrhagic stroke or ischemic stroke and TIAs were included on the basis of the fact that the majority of acute cerebrovascular events represent ischemic strokes.^{21, 22} Prospective studies examining ischemic stroke events over follow-up, but not excluding individuals with a history of prevalent stroke at baseline, were also included in our review, as long as such individuals represented the minority (<50%) of the baseline population.

Data extraction

A predefined spreadsheet was used to extract the following variables from each eligible study: publication details (author, year), study parameters (geographical origin, recruitment period, design, sample size, follow-up information), demographic population characteristics (age, sex, race), baseline cardiovascular risk factors (body mass index, diabetes mellitus, atrial fibrillation, coronary artery disease, hypertension, smoking status, hypercholesterolemia), IL-6 quantification details (sample, laboratory kit, storage temperature, scale of qualification), ischemic stroke assessment (definition, clinical scales used, imaging modality, number of cases), and statistical analysis details (analysis type, effect estimates, 95% CI, adjusting variables). Where supplementary data were needed, the corresponding author was contacted.

Risk of bias assessment

We evaluated studies for risk of bias using the eight-item cohort subscale of the Newcastle-Ottawa scale (NOS).²³ We opted to use 2 comparability criteria and therefore the total number of points scored totaled to nine. Specifically, the following criteria were assessed: (i) representativeness of the exposed cohort: a point was awarded when individuals were drawn from the general population and included both males and females; (ii) selection of the non-exposed cohort: a point was awarded when individuals were drawn from the same community as the exposed; (iii) exposure ascertainment: a point was awarded when the blood drawing protocol and the kit used for IL-6 quantification were reported; (iv) outcome presence at start of study: a point was awarded when individuals with a history of ischemic stroke at baseline were excluded from the analysis; (v and vi) two items for comparability: one point was awarded if the study adjusted for age (due to the well-established effect of age on circulating IL-6 levels²⁴) and sex. A second point was awarded if the study additionally adjusted for conventional vascular risk factors (at least lipids, blood pressure, diabetes mellitus and body mass index). Of note, systolic blood pressure and non-HDL cholesterol have been linked to circulating IL-6 levels^{25, 26}; (vii) outcome assessment: a point was awarded when the study presented association estimates specifically for ischemic stroke, excluding TIAs and hemorrhagic strokes, as well as when a clear definition was provided and each event was confirmed by at least a trained physician; (viii) length of follow-up: a point was awarded when the mean or median follow-up of the cohort was >5 years; (ix) adequacy of follow up cohorts: a point was awarded when the attrition rate was <10%.

Statistical analysis

For each eligible study we extracted association estimates and 95% CI between circulating IL-6 levels and incident ischemic stroke. Out of the 11 studies included in our meta-analysis, 8 presented hazard ratios (HR), 2 odds ratios (OR) and 1 relative risk (RR). First, we transformed all estimates and their corresponding 95% CI to RR. If ischemic stroke incidence in the examined cohort exceeded 10%, we used validated formulae, whereas in studies with <10% incidence, we considered HR and OR to be very close to RR and thus applied no transformation.²⁷ We carried out a meta-analysis on RR (rather than HR), since this was the most feasible transformation able to incorporate all available data (OR cannot be converted to HR due to inapplicability of the proportional hazards assumption). Overall, we performed a total of 3 transformations (2 OR and 1 HR to RR); the remaining RR were considered similar to HR due to <10% stroke incidence in the respective studies.²⁷

Seven out of the 11 studies analyzed 1-SD increment in log-transformed IL-6 (log-IL-6) levels, whereas the remaining 4 studies presented association estimates across tertiles or quartiles of IL-6. To enable a meta-analysis across all studies, we used the method of generalized least squares for trend estimation of summarized dose-response data to derive association estimates per 1-SD increment in studies presenting analyses in tertiles or quartiles.^{28, 29} Doses across each category were calculated as fitting SD-increases by using the median values of each tertile/quartile projected on a normal

distribution. We opted to perform a meta-analysis of effect estimates for 1-SD increment in log-IL-6 levels due to the heterogeneity in IL-6 measurement methods among the different studies. This approach is in line with other published studies exploring associations between circulating cytokines and cardiovascular endpoints^{16, 30} and is generally widely used for standardizing in meta-analyses of quantitative traits that have been assessed by different methods across studies.³¹

We then performed random-effect meta-analyses of the derived association estimates using the method described by DerSimonian and Laird³² and obtained a pooled RR with 95% CI for the risk of incident ischemic stroke per 1-SD increase in log-IL-6 levels. The presence of heterogeneity was evaluated by the I^2 , calculated via the Cochran Q statistic. We defined low, moderate, and high heterogeneity as an I^2 of <25%, 25% to 75%, and >75%, respectively.³³

To explore the robustness of our findings, we carried out sensitivity analyses restricted to: (i) studies of the general population; (ii) studies not including TIAs as an outcome; (iii) studies exclusively exploring ischemic stroke; (iv) studies excluding individuals with a history of prevalent stroke at baseline; (v) studies providing imaging confirmation (via CT or MRI) for an infarction beyond the clinical definition of ischemic stroke; (vi) studies adjusting their results for demographic and conventional vascular risk factors; (vii) studies additionally adjusting for circulating CRP; and (viii) studies fulfilling at least 8 out of the 9 quality criteria of NOS. We also ran a separate analysis of the 7 studies using the High Sensitivity 600 Quantikine ELISA kit by R&D Systems for quantifying circulating IL-6 levels to avoid heterogeneity in the effects due to differences in the used kit. Additionally, we performed the following subgroup analyses: (i) type of blood sample

used for IL-6 quantification (plasma or serum), (ii) type of prospective study design (cohort, nested case-control, case-cohort, or secondary analysis of RCT); and (iii) duration of follow-up (the median value of follow-up time was used as cut-off). To exclude potential outlier effects of individual studies, a “leave-one-out” sensitivity analysis was performed. Finally, to explore the potential impact of our effect estimate transformations, we performed a separate analysis restricted to studies with published HR estimates.

Furthermore, we sought to examine whether circulating IL-6 levels follow a linear association with the risk of incident ischemic stroke. We used a restricted cubic spline model with three knots (10%, 50%, 90%) to demonstrate the actual shape of the relationship between the RR for incident ischemic stroke plotted against IL-6 percentiles (more details available on **Appendix e-1**). For this analysis only studies presenting associations with stroke on 3 or more “levels” of IL-6 were eligible (e.g., tertiles, quartiles, etc.).

Additionally, taking into account the wide range of mean follow-up duration among studies, we chose to perform a meta-regression analysis on the association of 1-SD log-IL-6 increase with the RR of ischemic stroke plotted against study mean follow-up time.

The effect of potential publication bias (small-study effects) was explored using the Egger’s test³⁴ when >10 studies were pooled together, since the statistical power of the test is low in cases of ≤ 10 pooled studies.³⁵ Where evidence of small-study effects ($p > 0.10$) was detected, we further adjusted the pooled effect estimate for publication

bias using a “trim and fill” analysis.³⁶ The results were graphically presented with a funnel plot.

All analyses were based on aggregate data and conducted with the STATA Software, version 16.1 (Stata Corporation, College Station, TX, USA).

Standard Protocol Approvals, Registrations, and Patient Consents

This meta-analysis was solely based on aggregate data and therefore no Institutional Review Board approval was necessary. All individual studies have received ethical approval and in every occasion all patients have provided informed consent for participation into the respective study.

Data availability

Data not provided in the article due to space limitations will be made available upon reasonable request to the corresponding author.

RESULTS

Review of literature

Figure 1 summarizes the study selection process. Following an initial screening of 2,702 articles yielded by the literature search, we identified 8 articles,^{17-19, 37-41} referring

to 11 individual studies (n=27,411), meeting our eligibility criteria. Four of the included studies (DHS, FHS-offspring, MONICA/KORA and MDCS-CV) have not published results on the associations between circulating IL-6 levels and risk of ischemic stroke, but the respective data were provided as part of a secondary analysis in a recent meta-analysis focusing on the association of monocyte chemoattractant protein-1 with stroke.³⁹ Association estimates from the latter meta-analysis were used for the purposes of the current study.

Descriptive study characteristics and risk of bias assessment

Summarized descriptive characteristics of the 11 included studies are presented in **Table 1** and **Table e-1**. Mean age of all individuals was 60.5 years (study range, 44.0 to 75.9 years) and 54.8% of the study participants were females. Mean duration of follow-up was 12.4 years (study range, 3.2 to 20.0 years). All included studies followed a prospective study design: seven of them (n=21,384) featured a cohort study design, while the remaining 4 studies presented either case-cohort (k=2, n=3,425) or nested case-control (k=2, n=2,602) analyses within larger cohorts. Nine of the studies (n=26,149) were based on general population individuals, while 2 (n=1,262; OSAKA and PROSPER) were restricted to high-risk individuals with at least one conventional vascular risk factor. IL-6 measurements were made on blood drawn at baseline (stored at -70 to -80° C until analyzed). Four studies (n=7,813) used serum and 4 (n=10,813) used plasma samples to quantify IL-6, whereas the exact sample was not reported in 3 studies. The kit most commonly used for IL-6 measurements was the High Sensitivity

600 Quantikine ELISA by R&D Systems (7 studies; n=16,918). In 9 studies, where this was reported, intra- and inter-assay coefficients of variation were $\leq 10\%$.

Regarding outcome assessment, 9 studies (n=25,244) excluded patients with a history of stroke at baseline and 8 studies (n=18,105) specifically addressed ischemic stroke as their outcome excluding patients with hemorrhagic stroke or TIA. All endpoints were validated by at least two trained physicians, who reviewed each patient's medical or autopsy files. Only 3 studies (n=3,972) explicitly required imaging confirmation of an infarction with CT and/or MRI, as definition of ischemic stroke.

The overall study quality was high, with 5 of the studies (45.5%) fulfilling all 9 criteria of the Newcastle-Ottawa scale (**Table 1**). The median quality score was 8 out of 9 (interquartile range 7 to 9, range 3 to 9). The items "representativeness of the exposed cohort", "outcome not present at start of study", "assessment of outcome" and "length of follow-up" accounted for most non-awarded points. All studies controlled for age, sex (if the study included individuals of both sexes) and race (if the study included individuals of >1 race) and all but one of the studies additionally controlled for conventional vascular risk factors.

Circulating IL-6 and risk of incident ischemic stroke

In the meta-analysis of the 11 studies, we found a 1-SD increment in circulating log-IL-6 levels at baseline to be associated with a 19% higher risk of incident ischemic stroke over a mean follow-up of 12.4 years (RR 1.19; 95% CI 1.10 to 1.28; 27,411 individuals; 2,669 events, **Figure 2**). The results remained stable in sensitivity analyses for studies

excluding individuals with history of prevalent stroke at baseline, studies focusing on incident ischemic stroke explicitly excluding cases of TIA and hemorrhagic stroke, as well as studies requiring imaging confirmation of an infarction (**Figure 3**). All analyses controlled for age, sex and race. Furthermore, our analyses revealed that additional controlling for conventional vascular risk factors yielded the same pooled association estimate as our main analysis. Further adjustment for high-sensitivity CRP levels led to an anticipated attenuation of the association estimate, as CRP is downstream of IL-6,¹⁵ but the association remained statistically significant. Similar results were also obtained in a sensitivity analysis restricted to studies of low risk of bias (scoring at least 8 out of 9 in NOS). Restricting our analyses to studies quantifying IL-6 with the most commonly used High Sensitivity 600 Quantikine ELISA kit did not change the result. Of note, pooling a set of 6 studies of stroke-free individuals in the general population that specifically examined over a follow-up of >5 years associations with incident ischemic stroke (excluding TIAs and hemorrhagic strokes) and further adjusted for conventional vascular risk factors on top of age, sex and race yielded similar results (RR 1.16; 95% CI 1.07 to 1.25; 6 studies; 15,938 individuals; 2,029 events). Subgroup analyses by type of study design (cohort, case-cohort, nested case-control, secondary analyses of RCTs), type of blood sample used for IL-6 quantification (plasma, serum), and duration of mean follow-up time (≥ 11 and < 11 years) did not demonstrate a statistically significant subgroup difference (**Figure e-1**), while only pooling studies with HR effect estimates did not provide materially different results from our main analysis (**Figure e-2**). Finally, in “leave-one-out” sensitivity analyses, we found no evidence that any single study significantly influenced the results of our main analysis (**Figure e-3**).

The meta-regression analysis exploring the effect of follow-up time on the association of 1-SD log-IL-6 increase with the RR of ischemic stroke demonstrates that the RR is not dependent on the mean follow-up duration of the individual studies (beta coefficient - 0.0051; 95% CI -0.0219 to 0.0116; $p=0.505$; **Figure e-4**). Of note, a statistically significant negative slope (beta coefficient) would indicate that the relationship of IL-6 with stroke attenuates over time, possibly reflecting reverse causality. As such, the lack of this finding provides further support to the validity of our results.

There was only moderate heterogeneity in the main analysis ($I^2=44.6\%$, $p=0.05$; **Figure 2**), which was not entirely resolved in any of the sensitivity analyses (**Figure 3**). The funnel plot for our main analysis is presented in **Figure e-5**. Although the Egger's test detected small-study effects ($p=0.03$) indicating potential presence of publication bias, the association between circulating IL-6 levels and incident ischemic stroke remained stable (RR 1.14; 95% CI 1.05 to 1.24) after correcting our analysis for small-study effects with the "trim and fill" method.

As a final step, we aimed to explore the shape of the association between circulating IL-6 levels and risk of incident ischemic stroke. In a dose-response meta-analysis including data from 5 studies (13,385 individuals; 1,831 events), we found a linear relationship between circulating IL-6 levels and incident ischemic stroke (p for non-linearity: 0.52; **Figure 4**).

DISCUSSION

Pooling data from 11 population-based prospective cohort studies involving 27,411 individuals and 2,669 stroke events, we found higher circulating IL-6 levels at baseline to be associated with a higher risk of incident ischemic stroke over a mean follow-up of 12.4 years. IL-6 levels showed a linear relationship with the risk of ischemic stroke following a dose-response pattern. Overall, study quality was high and the results were stable in all sensitivity analyses, as well as when correcting for publication bias.

Our meta-analysis extends previous data related to the associations between circulating IL-6 levels with acute coronary events and other vascular phenotypes¹⁶ to ischemic stroke. IL-6 signaling has been demonstrated as one of the most promising targets for anti-inflammatory approaches in cardiovascular disease. The CANTOS trial tested canakinumab, a monoclonal antibody against IL-1b, which is upstream to IL-6, in patients with recent myocardial infarction and showed a beneficial effect against a combined cardiovascular endpoint, also involving stroke.⁶ Still, canakinumab led to relatively high rates of neutropenia and accompanying fatal infections, and there was very high inter-individual variation in drug response and efficacy.⁶ An under development monoclonal antibody that directly inhibits IL-6⁴² showed a better safety profile and more robust and uniform reductions in markers of IL-6 signaling activity. Interestingly, secondary analyses from CANTOS showed that the benefit was restricted to individuals in whom canakinumab resulted in meaningful reductions in IL-6 levels.⁴³ However, CANTOS could not specifically show benefit against stroke,⁶ possibly as a result of limited power. In line with the above, a recently published meta-analysis exploring the association of circulating IL-6 with recurrent stroke events provides further insight into the examined relationship.⁴⁴ The results from these meta-analyses, when

seen together with Mendelian randomization results supporting associations between lifetime genetically downregulated IL-6 signaling and lower ischemic stroke risk¹² provide further support in favor of IL-6 signaling as a promising target for lowering stroke risk.

An interesting finding from our analysis is the clearly log-linear dose-response relationship between IL-6 levels and stroke risk. Our results indicate an approximately 19% increment in risk of ischemic stroke per-SD increment in log-IL-6 levels. This magnitude of effect, along with the clear dose-response pattern, is comparable to the magnitude and shape of associations that have been reported for non-HDL cholesterol levels (12%, 95% CI: 4-20%),⁴⁵ and systolic blood pressure (24%, 95% CI: 15-35%),⁴⁶ both key therapeutic targets for lowering ischemic stroke risk. While this association estimate slightly reduced after correcting for publication bias, it still remained in the same order of magnitude (RR 1.14), thus supporting a meaningful association with the risk of ischemic stroke.

Our results should be viewed in the context of specific methodological strengths. First, this meta-analysis is clearly based on prospective cohort population-based studies with a relatively long follow-up period, thus precluding the possibility of reverse causation. Furthermore, our rigorous search of published literature, allowed us to pool a large sample size including more than 2,600 incident stroke cases, thus offering the power to explore interesting aspects of this association, such as its robustness against specific forms of bias in sensitivity analyses, and dose-response relationships. Finally, as observed in our risk of bias analysis, the quality of the included studies was generally high, thus further supporting the validity of the results.

Our study also has limitations. There was moderate heterogeneity in the main analysis ($I^2=45\%$), which points to key methodological differences between individual studies. Specifically, while all of the studies had a prospective study design, some of them applied case-cohort or nested case-control approaches within the larger cohorts. Furthermore, there were wide differences with regard to mean follow-up intervals ranging from 3 to 20 years across studies. Similarly, there were between-study differences regarding the definition of the outcomes, with some of the studies focusing only on stroke as a whole and not ischemic stroke, whereas other studies also included TIAs. Heterogeneity was also evident among variables controlled for across the individual studies (**Table e-1**), while data were lacking on some key mediating factors, such as large-vessel atherosclerosis. Still, it should be mentioned that the results were stable in all sensitivity analyses, even the one focusing on imaging-confirmed infarctions. Of note, it was not possible to present results on ischemic stroke etiologic subtypes, since the individual studies did not present quantitative data on these outcomes. Another source of heterogeneity is the method used for measuring IL-6 levels, for which, as opposed to high-sensitivity CRP, there are no standard clinical platforms for quantification. To address this issue, we performed all our analyses based on standardized (1-SD) log-IL-6 levels, under the assumptions that (i) log-IL-6 follows a normal distribution,⁴⁷ and (ii) the association of IL-6 with the relative risk of ischemic stroke is linear, as we demonstrated in our analysis (**Figure 4**). Nonetheless, differences between studies might persist and might affect the results. Additionally, this approach does not allow for a direct interpretation of our findings to absolute IL-6 levels, which would be more relevant in every-day clinical practice. Finally, there was evidence

of small-study effects indicating publication bias in our analysis, but the results were stable after correcting for it with the trim and fill method.

We assume the observed association between circulating IL-6 levels and incident stroke to be explained by an effect of IL-6 signaling on pathologies underlying ischemic stroke, especially large artery atherosclerotic stroke.^{12, 48} However, it should be noted that IL-6 levels might be transiently influenced by acute inflammatory responses, as is the case in infections, and thus single measurements might not necessarily reflect IL-6 signaling activity in the vasculature. Beyond transient increases, IL-6 levels have been found to be genetically determined to a large extent (up to 61%),⁴⁹ whereas advanced age and vascular risk factors have also been found to be associated with higher IL-6 levels.²⁴⁻²⁶ While serial IL-6 measurements would reduce noise from acute inflammatory responses, we believe that in the context of a general population sample mainly comprised of healthy middle-aged individuals, transient variation in IL-6 levels would be rather uncommon. Furthermore, previous analyses of serial IL-6 measurements have found a large proportion of variation in IL-6 levels to be due to between-person differences and not within-individual variation over time, thus suggesting that single cross-sectional measurements can offer useful insights.⁵⁰

In summary, as illustrated in our meta-analyses, data from observational studies support a clear dose-response association between circulating IL-6 levels and risk of incident ischemic stroke among stroke-free individuals at baseline. While these results cannot establish causality, when triangulated with evidence from human genetic data, as well as indirect evidence from clinical trials, they provide further support for IL-6 signaling as a promising target for lowering the risk of ischemic stroke. The patient

subgroup that would ultimately benefit from anti-IL-6 treatment remains to be determined in future well-organized randomized clinical trials.

Appendix 1: Authors

Name	Location	Contribution
Andreas Papadopoulos, MD	401 General Military Hospital of Athens, Greece	concept and design; data acquisition, analysis, and interpretation of data; statistical analysis; drafting of the manuscript
Konstantinos Palaiopanos, MD	National Public Health Organization, Athens, Greece	data acquisition, analysis, and interpretation of data; drafting of the manuscript
Harry Björkbacka, PhD	Lund University, Malmö, Sweden	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Annette Peters, PhD	Helmholtz Zentrum München, Germany	data acquisition; critical revision of the manuscript for intellectual content; study supervision
James A. de Lemos, MD	University of Texas Southwestern Medical Center, Dallas, TX, USA	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Sudha Seshadri, MD	University of Texas Health Sciences Center, San Antonio, TX, USA	data acquisition; critical revision of the manuscript for intellectual content; study supervision
Martin Dichgans, MD	LMU Munich, Germany	interpretation of data; critical revision of the manuscript for intellectual content; study supervision
Marios K. Georgakis, MD, PhD	LMU Munich, Germany	concept and design; data acquisition, analysis, and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for intellectual content; study supervision

REFERENCES

1. GBD-2017-Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1736-1788.
2. GBD-2019-Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1204-1222.
3. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. *Nat Rev Neurol* 2016;12:594-604.
4. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol* 2009;54:2129-2138.
5. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med* 2020;383:1838-1847.
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017;377:1119-1131.
7. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med* 2019;381:2497-2505.
8. Katsanos AH, Palaiodimou L, Price C, et al. Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. *Eur J Neurol* 2020;27:1035-1038.

9. Georgakis MK, Gill D, Rannikmäe K, et al. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. *Circulation* 2019;139:256-268.
10. Kelly PJ, Murphy S, Coveney S, et al. Anti-inflammatory approaches to ischaemic stroke prevention. *J Neurol Neurosurg Psychiatry* 2018;89:211-218.
11. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375:132-140.
12. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M. Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes: A Mendelian Randomization Study. *Circ Genom Precis Med* 2020;13:e002872.
13. Georgakis MK, Malik R, Li X, et al. Genetically Downregulated Interleukin-6 Signaling Is Associated With a Favorable Cardiometabolic Profile: A Phenome-Wide Association Study. *Circulation* 2021:1177-1180.
14. Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 2012;379:1214-1224.
15. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. *Circ Res* 2016;118:145-156.
16. Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart J* 2014;35:578-589.
17. Jenny NS, Callas PW, Judd SE, et al. Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort. *Neurology* 2019;92:e2375-e2384.

18. Kaplan RC, McGinn AP, Baird AE, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. *J Stroke Cerebrovasc Dis* 2008;17:344-355.
19. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. *Atherosclerosis* 2010;209:551-557.
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj* 2009;339:b2700.
21. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376:112-123.
22. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* 2005;366:1773-1783.
23. Wells G SB, O'Connell D, Peterson J, Welch V, Losos M, et al. The newcastle-ottawa scale (nos) for assessing the quality if nonrandomized studies in meta-analyses; available at: http://www.Ohri.Ca/programs/clinical_epidemiology/oxford.Asp, accessed October 3, 2021. [online].
24. Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. *Immun Ageing* 2016;13:21.

25. DiNicolantonio JJ, McCarty MF. Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly? *Open Heart* 2018;5:e000789.
26. Tanase DM, Gosav EM, Radu S, et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? *Int J Hypertens* 2019;2019:3159283.
27. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. *Biometrics* 2020;76:746-752.
28. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol* 1992;135:1301-1309.
29. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol* 2012;175:66-73.
30. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. *PLoS Med* 2008;5:e78.
31. Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. *Am J Epidemiol* 1996;144:610-621.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-188.

33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj* 2003;327:557-560.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;315:629-634.
35. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol* 2000;53:1119-1129.
36. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455-463.
37. Cainzos-Achirica M, Enjuanes C, Greenland P, et al. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis* 2018;278:217-225.
38. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. *Circulation* 2003;108:2317-2322.
39. Georgakis MK, Malik R, Björkbacka H, et al. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17□180 Individuals. *Circ Res* 2019;125:773-782.
40. Miwa K, Tanaka M, Okazaki S, et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. *Arterioscler Thromb Vasc Biol* 2013;33:400-405.
41. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older people: a nested case-control study. *Int J Epidemiol* 2009;38:253-261.

42. Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet* 2021;397:2060-2069.
43. Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J* 2018;39:3499-3507.
44. McCabe JJ, O'Reilly E, Coveney S, et al. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis. *Eur Stroke J* 2021;6:62-71.
45. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. *Jama* 2009;302:1993-2000.
46. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. *Arch Intern Med* 2001;161:1183-1192.
47. Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. *Lancet Respir Med* 2016;4:574-584.
48. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. *Circ Res* 2021;128:1728-1746.
49. Wörns MA, Victor A, Galle PR, Höhler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels--a study in twins. *Genes Immun* 2006;7:600-605.

50. Arnberg FK, Lekander M, Morey JN, Segerstrom SC. Self-rated health and interleukin-6: Longitudinal relationships in older adults. *Brain Behav Immun* 2016;54:226-232.

Values are reported as n (%), mean (SD) or median (25th-75th percentile), unless otherwise stated.

NR = not reported; ELISA = enzyme-linked immunoassay; BMI = body mass index; CAD = coronary artery disease; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL-C = low-density lipoprotein cholesterol.

*Aggregate data were provided as part of a secondary analysis in a recent meta-analysis focusing on the association of monocyte chemoattractant protein-1 with stroke.⁴¹ †Median (IQR). ‡Geometric means. §Refers to human IL-6 Quantikine High Sensitivity (HS) ELISA Kit (HS600) by R&D Systems. ¶Refers to total stroke cases (ischemic + hemorrhagic). ¶¶Refers to total stroke cases (ischemic + hemorrhagic) and TIAs. ¶¶¶Individuals under anti-hypertensive or lipid-lowering medication(s). ¶¶¶¶Selection items include: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and exclusion of outcome presence at start of study; comparability items include: comparability for age and sex (if applicable) and comparability for conventional vascular risk factors; outcome items include: assessment of outcome, length of follow-up, and adequacy of follow-up cohorts. The items are scored in the order mentioned; ☐ indicates that the study is awarded a point at the respective criterion.

FIGURE TITLES AND LEGENDS

Figure 1. Flowchart of the study selection process. Steps and number of articles screened per step during the study selection process.

CVE = cardio-vascular events.

Figure 2. Meta-analysis of the association between circulating log-IL-6 levels (1-SD increment) and risk of incident ischemic stroke. Risk ratios (RR) of each study are depicted as data markers; black boxes around the data markers indicate the statistical weight of the respective study; 95% CI are indicated by the black error bars; pooled-effect estimate along with its 95% CI is reflected as a black diamond. This analysis controlled for age, sex and race.

Figure 3. Sensitivity analyses of the association between circulating log-IL-6 levels (1-SD increment) and risk of incident ischemic stroke. Pooled random-effect risk ratios (RR) of each analysis are presented as green data markers; 95% CI are indicated by the black error bars; the vertical green dashed line indicates the overall effect estimate of the main analysis.

* High Sensitivity 600 Quantikine ELISA by R&D Systems.

ELISA = enzyme-linked immunosorbent assay; CRP, C-reactive protein; NOS = Newcastle - Ottawa scale. All sensitivity analyses controlled for age, sex and race.

Figure 4. Dose-response meta-analysis of the association between circulating IL-6 levels (standardized values in percentiles) and risk of incident ischemic stroke. A double-tail restricted, 3 cubic knot (10%, 50%, 90%) flexible model was used. IL-6 levels have been projected on a normal distribution and are presented as percentiles. The median of the 1st quartile (12.5th percentile) is used as the reference. The analysis is based on 5 studies (13,385 individuals; 1,831 stroke

cases). This analysis controlled for age, sex, race and conventional vascular risk factors.







